First Patient Enrolled in Pivotal Atherectomy Clinical Study

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

Athar Ansari, MD, FACC, Director of the California Heart & Vascular Clinic in El Centro, Calif. and the study chairman said, “My extensive experience with DABRA in treating infrainguinal vascular occlusions gives me confidence in the safety and efficacy of the device.” He added, “We are thrilled to be the first center to begin enrollment in the atherectomy study, which represents an important next step in expanding the DABRA indications for use.”

“We are committed to the successful commercialization of DABRA and we believe that initiating patient enrollment in this study is a significant step forward in achieving this goal,” said Andrew Jackson, Ra Medical Systems CFO and Interim CEO. “Furthermore, we have built a team of experienced, motivated and enthusiastic physician partners and employees to execute on this goal and we look forward to providing updates on our progress.”

Ra Medical received investigational device exemption (IDE) approval for the study from the FDA in January 2020. This multicenter, open-label pivotal atherectomy clinical study will enroll up to 100 patients with symptoms of PAD (Rutherford Class 2-4). Outcome measures include safety, acute technical success and clinical success. The trial’s primary efficacy endpoint is the mean reduction in percent diameter stenosis in each patient’s primary lesion as measured by angiography immediately following treatment with DABRA, before any adjunctive treatment. Major adverse events at 30 days and incidence of primary target lesion revascularization (TLR) at six months will be the safety and clinical success endpoints.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine

Related Articles